Literature DB >> 2125250

Bone marrow transplantation in canine GM1 gangliosidosis.

J S O'Brien1, R Storb, R F Raff, J Harding, F Appelbaum, S Morimoto, Y Kishimoto, T Graham, A Ahern-Rindell, S L O'Brien.   

Abstract

Allogeneic bone marrow transplantation was carried out in an 81-day-old Portuguese water dog with GM1 gangliosidosis using a DLA identical sibling as donor. Engraftment was complete and beta-galactosidase activity in leukocytes of the transplanted dog were similar to those in the donor. Over the next 2.5 months neurological deterioration in the transplanted dog was similar to that in untreated dogs with GM1 gangliosidosis. Cerebral ganglioside GM1 concentrations were not diminished by bone marrow transplantation and cerebral beta-galactosidase activity was negligible. We conclude that allogeneic bone marrow transplantation early in life is ineffective in canine GM1 gangliosidosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125250     DOI: 10.1111/j.1399-0004.1990.tb03581.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Bone marrow transplantation correcting beta-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis.

Authors:  J P H Shield; J Stone; C G Steward
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

Authors:  Debra S Regier; Richard L Proia; Alessandra D'Azzo; Cynthia J Tifft
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

3.  Beta-galactosidase deficiency: an approach to chaperone therapy.

Authors:  Yoshiyuki Suzuki
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

4.  Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.

Authors:  V J McCurdy; H E Rockwell; J R Arthur; A M Bradbury; A K Johnson; A N Randle; B L Brunson; M Hwang; H L Gray-Edwards; N E Morrison; J A Johnson; H J Baker; N R Cox; T N Seyfried; M Sena-Esteves; D R Martin
Journal:  Gene Ther       Date:  2014-12-04       Impact factor: 5.250

5.  Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter.

Authors:  C N Hahn; M del Pilar Martin; X Y Zhou; L W Mann; A d'Azzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

7.  Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.

Authors:  M Lupu; R Storb
Journal:  Vet Comp Oncol       Date:  2007-03       Impact factor: 2.613

Review 8.  Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Med Sci       Date:  2021-08-14

9.  A Single Injection of an Optimized Adeno-Associated Viral Vector into Cerebrospinal Fluid Corrects Neurological Disease in a Murine Model of GM1 Gangliosidosis.

Authors:  Christian Hinderer; Brenden Nosratbakhsh; Nathan Katz; James M Wilson
Journal:  Hum Gene Ther       Date:  2020-11-02       Impact factor: 5.695

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.